Tag

Journal of Drugs in Dermatology

Sep 10 2019
Love2
ndrew Alexis receiving JDD award for Innovations in Dermatology from Skin of Color Update

ANDREW F. ALEXIS, MD, MPH, PRESENTED WITH INNOVATIONS AWARD

By Press

NEW YORK (Sept. 9, 2019) – The Journal of Drugs in Dermatology (JDD) presented dermatologist Andrew F. Alexis, MD, MPH, with the Innovations in Skin of Color Dermatology Award at Skin of Color Update, formerly Skin of Color Seminar Series, held September 7 and 8 in New York. The award recognizes individuals who have fostered innovation and improvement in dermatology through increased emphasis on skin of color education and research. If you missed the event, you can purchase lectures on-demand here.

“Andrew F. Alexis, MD, MPH is committed and passionate — not only about being the best dermatologist he can be – but also about bringing skin of color education to dermatology,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD and Skin of Color Update. “Through his efforts, the changing landscape of patients can now thrive through treatment and management plans that address their specific needs.”

“Dr. Alexis is the top innovator in the dermatologic and cosmetic treatment of patients with skin of color,” said dermatologist Eliot F. Battle, MD, co-chair of Skin of Color Update along with Dr. Alexis. “His decades of pioneering research in dermatology have led to the development of new procedures and products that address a wide range of dermatologic conditions. He compassionately treats his patients, shares his expertise by presenting throughout the world and gives back through mentoring the next generation of dermatologists and researchers. I am honored to serve alongside this distinguished innovator.”

Dr. Alexis is chair of the department of dermatology and director of the Skin of Color Center at Mount Sinai St. Luke’s and Mount Sinai West, New York. As such, he is actively involved in advancing patient care, research and education pertaining to dermatologic disorders that are prevalent in ethnic skin. He is also professor of dermatology at the Icahn School of Medicine at Mount Sinai.

Dr. Alexis received his medical degree from Columbia University College of Physicians & Surgeons and his Master of Public Health at Columbia University’s Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medical Center, followed by a fellowship in dermatopharmacology at New York University School of Medicine.

Dr. Alexis has published more than 70 articles in peer-reviewed journals and has co-edited two text books on dermatology for skin of color as well as authored 10 book chapters. He is a past president of the New York Dermatological Society and is currently chair of the Scientific Committee of the Skin of Color Society.

The recipient of the Innovations in Skin of Color Dermatology Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders.

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports and timely features pertaining to new methods, techniques and drug therapy that provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

Skin of Color Update 2020 will be held September 12th – 13th at the Sheraton Times Square.

Media Contact:
Allison Sit
[email protected]

Purchase Skin of Color Update On-Demand: 

Skin of Color Update Dermatology On-Demand

Aug 08 2019
Love1
Adam Friedman at ODAC

GW RESEARCHERS IDENTIFY BARRIER TO FUNGAL INFECTION DIAGNOSIS

By Press

In a recent survey, researchers identified the barriers to accurately diagnosing cutaneous fungal infections

August 8, 2019

WASHINGTON (Aug. 8, 2019) —There are several barriers that prevent the consistent use of fungal diagnostic preparations to correctly identify cutaneous fungal infections, according to a survey from a team at the George Washington University (GW). The study is published in the Journal of Drugs in Dermatology.

Cutaneous fungal infections account for between 3.5 and 6.5 million dermatologist office visits per year. Despite their frequency, the diverse presentations of fungal infections often lead to misdiagnosis, resulting in additional costs, time, and delays in proper care. Direct microscopy using potassium hydroxide (KOH) or other stains provides an inexpensive method to diagnose fungal infections. However, this requires clinics to have the Clinical Laboratory Improvement Amendment (CLIA) certification.

“Because of the extraordinary ability for these fungal infections to mimic other skin diseases, identification based on clinical inspection alone can often lead to misdiagnosis and mismanagement,” said Adam Friedman, MD, professor and interim chair of the Department of Dermatology at the GW School of Medicine and Health Sciences and senior author on the study. “Little is known regarding the frequency with which dermatologists use these simple, yet diagnosis changing bedside fungal preparations, nor do we know if and what barriers exist preventing accurate diagnosis of infections.”

Friedman’s team previously published research highlighting the difficulty even dermatologists have when distinguishing between skin fungal infections and other inflammatory skin diseases, highlighting the importance of using laboratory-based tools to aid in patient care.

This survey, led by Emily Murphy, a research fellow in the Department of Dermatology at the GW School of Medicine and Health Sciences, was distributed via email to participants of the ODAC Dermatology Aesthetic and Surgical Conference, and the data was compiled in a web-based platform. Of the respondents, around 21% indicated they rarely/never perform fungal preparations and about 20% reported they sometimes do, often because they think clinical diagnosis is adequate or because fungal preparations take too long. Additionally, about 21% of respondents reported not having CLIA certifications, mostly because the process requires too much work or because they do not know how to apply. Of the providers who have CLIA certification, more than 25% reported that it was difficult to obtain.

“Our results indicate the need for increased education about the many clinical faces of cutaneous fungal infections and proper use of bedside diagnostics,” Friedman said. “It also highlights the need for policy-based interventions in order to ease the process of CLIA certification, to ensure that dermatology clinics are equipped to accurately diagnose infections.”

The study, titled “Use of In-Office Preparations by Dermatologists for the Diagnosis of Cutaneous Fungal Infections,” published in the Journal of Drugs in Dermatology can be found at jddonline.com/articles/dermatology/S1545961619P0798X/1/.

Media: For more information or to set up an interview, please contact Ashley Rizzardo at [email protected] or 202-994-8679.

###

About the GW School of Medicine and Health Sciences
Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation’s capital and is the 11th oldest in the country. Working together in our nation’s capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. smhs.gwu.edu

Jun 18 2019
Love3
All new JDDonline.com

NEWLY REDESIGNED JDDONLINE PROVIDES FASTER, MORE USER-FRIENDLY

By Press

NEWLY REDESIGNED JDDONLINE PROVIDES FASTER, MORE USER-FRIENDLY

ACCESS TO THE JOURNAL OF DRUGS IN DERMATOLOGY

New York (June 18, 2019)– The Journal of Drugs in Dermatology (JDD) has a newly revamped website, JDDonline.com, which offers a fully-responsive design for more user-friendly browsing. With updated navigation, seamless transition from desktop to mobile viewing and new search features, subscribers are able to access JDD content, renew their subscriptions and view multimedia faster and easier than ever before.

“Our goal is to get the latest dermatologic research into the hands of clinicians as quickly and easily as possible so that the latest advancements can be further researched and implemented,” said Shelley Tanner, CEO and president of SanovaWorks, parent company of the JDD.

The redesigned site makes it easier to navigate the journal’s award-winning content, including multimedia, such as the JDD Podcastand Translational Lecture Series. In addition, subscribers can view PDFs of articles and archived issues.

The journal has also launched a new manuscript submission and peer-review site. The updated, streamlined submission process facilitates compliance with publishing requirements and allows fast, easy upload of manuscript files, figures and materials. The manuscript submission site can be accessed from JDDonline.comby clicking on the Authors tab at the top of the page or by visiting the site directly at jdd.msubmit.net.

“The manuscript submission process is easy to follow, which ensures completeness, quality control and timely submission,” Tanner said. “From the submission process to the final product, the Journal of Drugs in Dermatologystrives to be the leader in dermatologic publishing.”

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports and timely features pertaining to new methods, techniques and drug therapy that provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

 

Media Contact:

Allison Sit

[email protected]

Feb 13 2019
Love1
Burt's Bees and Dermatology Journal of Drugs in Dermatology study

JDD PUBLISHES STUDY ON CLINICAL IMPROVEMENTS WITH BURT’S BEES’ SENSITIVE SKIN REGIMEN AS ADJUNCT TO ROSACEA THERAPY

By Press

Journal of Drugs in Dermatology Publishes Study Showcasing Clinical Improvements with Burt’s Bees’ Sensitive Skin Regimen as Adjunct to Rosacea Prescription Therapy

Data Demonstrating Regimen’s Outperformance of a Dermatologist-Recommended Control to be presented at American Academy of Dermatology Annual Meeting

DURHAM, N.C.–(BUSINESS WIRE)–Burt’s Bees, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of Burt’s Bees skin care products as an adjunct to rosacea prescription therapy. Abstracts outlining the study data will be shared at the American Academy of Dermatology Annual Meeting on March 1-5, 2019, in Washington, D.C.

For access to the manuscript click here.

Click here to read the complete press release.

Apr 27 2018
Love2
Acne Genetic Twins Survey JDD

ACNE SURVEY AT WORLDS LARGEST TWINS CONVENTION AFFIRMS GENETIC LINK

By Press

Study also reveals social and environmental factors that influence acne severity

NEW YORK, April 27, 2018 /PRNewswire/ — A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, Ohio, and published in the April issue of the Journal of Drugs in Dermatology, shows the skin condition may be primarily caused by genetics. Study findings show the proportion of pairs where twins have acne was significantly higher in identical (64 percent) versus fraternal (49 percent) twins.

“Since identical twins have the same genetic makeup, they make the perfect study group to see if acne is caused more by genetics or environmental factors,” said dermatologist Elma Baron, MD, professor of dermatology at Case Western Reserve University, Cleveland, and chief of dermatology at Louis Stokes Cleveland VA Medical Center.

Participating in the survey were 202 (101 pairs) identical and 53 (26 sets) fraternal twins, including one set of fraternal triplets. Both groups were young, predominantly female and the majority of the participants were Fitzpatrick Skin Types II or III. The survey was conducted at the 2016 festival.

Researchers also attempted to determine social and environmental factors that influence acne severity. A twin-to-twin analysis of 56 identical twin pairs who had acne yet differed in self-reported severity revealed differences that may serve as triggers, including a high-glycemic diet, higher BMI, and lower frequency of exercise compared to twins without acne.

“There is some suggestion that factors other than genetics may contribute to acne severity,” said Dr. Baron. “As was demonstrated in our study and others, people genetically predisposed to acne can reduce the intake of sugar and refined carbohydrates to help keep acne on the mild side. Using cosmetics that are non-comodegenic can also help reduce acne severity.”

Survey participants were also asked additional health questions to discover possible associations with other health conditions. Identical twins with acne were found to have a higher incidence of polycystic ovarian syndrome (PCOS), anxiety and asthma.

“Other studies have linked acne with PCOS and anxiety, but further research is needed to determine if there is a true association between acne and asthma,” said Dr. Baron.

The study may be accessed at: http://jddonline.com/articles/dermatology/S1545961618P0380X/1.

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 17th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology, which provides readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 150 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide. The JDD is a product of SanovaWorks.

Media Contact:
Allison Sit
[email protected]

SOURCE SanovaWorks